BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36180422)

  • 41. Plasma Extracellular Vesicle-Derived TIMP-1 mRNA as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma: A Pilot Study.
    Dias F; Teixeira AL; Nogueira I; Morais M; Maia J; Bodo C; Ferreira M; Vieira I; Silva J; Lobo J; Sequeira JP; Maurício J; Oliveira J; Palmeira C; Martins G; Kok K; Costa-Silva B; Medeiros R
    Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32610589
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype.
    Kammerer-Jacquet SF; Brunot A; Pladys A; Bouzille G; Dagher J; Medane S; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Edeline J; Laguerre B; Lespagnol A; Mosser J; Dugay F; Belaud-Rotureau MA; Rioux-Leclercq N
    Clin Genitourin Cancer; 2017 Feb; 15(1):e1-e7. PubMed ID: 27444986
    [TBL] [Abstract][Full Text] [Related]  

  • 43. STEAP3 can predict the prognosis and shape the tumor microenvironment of clear cell renal cell carcinoma.
    Wu J; Bi Q; Zheng X; Cao H; Hao C; Sun Z; Wang W
    BMC Cancer; 2022 Nov; 22(1):1204. PubMed ID: 36424540
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-level S100A6 promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma.
    Lyu X; Li H; Ma X; Li X; Gao Y; Ni D; Shen D; Gu L; Wang B; Zhang Y; Zhang X
    Cell Biochem Biophys; 2015 Jan; 71(1):279-90. PubMed ID: 25120023
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Myoferlin silencing inhibits VEGFR2-mediated proliferation of metastatic clear cell renal cell carcinoma.
    An HJ; Song DH; Koh HM; Kim YM; Ko GH; Lee JH; Lee JS; Yang JW; Kim MH; Seo DH; Jang SM; Kim DC
    Sci Rep; 2019 Sep; 9(1):12656. PubMed ID: 31477752
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Upregulation of CENPM is associated with poor clinical outcome and suppression of immune profile in clear cell renal cell carcinoma.
    Zhang ZC; Liu YF; Xi P; Nie YC; Sun T; Gong BB
    Hereditas; 2023 Jan; 160(1):1. PubMed ID: 36635779
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
    Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
    Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane.
    Ishihara M; Hu J; Zhang X; Choi Y; Wong A; Cano-Ruiz C; Zhao R; Tan P; Tso JL; Wu L
    J Vis Exp; 2020 Feb; (156):. PubMed ID: 32091005
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Protein Arginine Methyltransferases Refine the Classification of Clear Cell Renal Cell Carcinoma with Distinct Prognosis and Tumor Microenvironment Characteristics.
    Ye S; Tian X; Anwaier A; Wei S; Liu W; Su J; Zhu S; Dai B; Gu J; Qu Y; Xu W; Zhang H; Ye D
    Int J Biol Sci; 2023; 19(14):4552-4570. PubMed ID: 37781030
    [No Abstract]   [Full Text] [Related]  

  • 50. A New Thinking: Deciphering the Aberrance and Clinical Implication of IGF Axis Regulation Pattern in Clear Cell Renal Cell Carcinoma.
    Jiang A; Wu X; Wang D; Wang A; Dong K; Liu B; Qu L; Luo P; Wang J; Tong Q; Wang L
    Front Immunol; 2022; 13():935595. PubMed ID: 35935986
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment
    Xu W; Lu J; Liu WR; Anwaier A; Wu Y; Tian X; Su JQ; Qu YY; Yang J; Zhang H; Ye D
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040418
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elevated expression of IFN-inducible CXCR3 ligands predicts poor prognosis in patients with non-metastatic clear-cell renal cell carcinoma.
    Liu W; Liu Y; Fu Q; Zhou L; Chang Y; Xu L; Zhang W; Xu J
    Oncotarget; 2016 Mar; 7(12):13976-83. PubMed ID: 26910919
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bioinformatics Analysis Suggests the Combined Expression of AURKB and KIF18B Being an Important Event in the Development of Clear Cell Renal Cell Carcinoma.
    Liu Q; Zhang X; Tang H; Liu J; Fu C; Sun M; Zhao L; Wei M; Yu Z; Wang P
    Pathol Oncol Res; 2020 Jul; 26(3):1583-1594. PubMed ID: 31489573
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CCL5-dependent mast cell infiltration into the tumor microenvironment in clear cell renal cell carcinoma patients.
    Liu T; Xia Q; Zhang H; Wang Z; Yang W; Gu X; Hou T; Chen Y; Pei X; Zhu G; He D; Li L; Xu S
    Aging (Albany NY); 2020 Nov; 12(21):21809-21836. PubMed ID: 33177244
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A tumor-specific microRNA signature predicts survival in clear cell renal cell carcinoma.
    Ge YZ; Wu R; Xin H; Zhu M; Lu TZ; Liu H; Xu Z; Yu P; Zhao YC; Li MH; Hu ZK; Zhao Y; Zhong B; Xu X; Zhou LH; Xu LW; Wu JP; Li WC; Zhu JG; Jia RP
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1291-9. PubMed ID: 25633718
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Single-cell transcriptomic analysis in clear cell renal cell carcinoma: Deciphering the role of APP within the tumour microenvironment.
    Guan B; Li M; Cui D; Shen C; Hao Z; Li X
    J Cell Mol Med; 2024 Mar; 28(6):e18186. PubMed ID: 38445803
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cuproptosis-Related MiR-21-5p/FDX1 Axis in Clear Cell Renal Cell Carcinoma and Its Potential Impact on Tumor Microenvironment.
    Xie M; Cheng B; Yu S; He Y; Cao Y; Zhou T; Han K; Dai R; Wang R
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611966
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of an immunogenic cell death-related gene signature predicts survival and sensitivity to immunotherapy in clear cell renal carcinoma.
    Zhou S; Lu Y; Chen Y; Gan W
    Sci Rep; 2023 Mar; 13(1):4449. PubMed ID: 36932108
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-dimensional Cytometry (ExCYT) and Mass Spectrometry of Myeloid Infiltrate in Clinically Localized Clear Cell Renal Cell Carcinoma Identifies Novel Potential Myeloid Targets for Immunotherapy.
    Theodros D; Murter BM; Sidhom JW; Nirschl TR; Clark DJ; Chen L; Tam AJ; Blosser RL; Schwen ZR; Johnson MH; Pierorazio PM; Zhang H; Ganguly S; Pardoll DM; Zarif JC
    Mol Cell Proteomics; 2020 Nov; 19(11):1850-1859. PubMed ID: 32737216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.